Why Advanced Micro Devices (AMD) Stock Rose 1.3% on Nov 10, 2026
as of Tuesday, 9:57 AM ET
The reason we found
AMD Gains on Google AI Deal and Strong Revenue Outlook
AMD is supplying EPYC processors for Google’s next-generation TPU system, reinforcing its role in expanding AI infrastructure and its rivalry with Nvidia. Separately, the company’s roughly $17 billion fourth-quarter revenue outlook suggests continued demand acceleration, providing fundamental support for today’s 2.4% gain.
business partnership and earnings outlookhigh confidence
Sources 9
- AMD Just Guided to More Revenue Than Intel. A Decade Ago Intel Was 12x Its Sizetikr.com
- AMD Stock Erases Its 17% Crash in Two Sessions, but Can It Clear $515.13? - TradingKeynews.google.com
- The AI Trade Looks Like It's Falling Apart. AMD's Earnings Delivered a Reality Check.nasdaq.com
- S&P 500: Just Three Of Nov. 5's 20 Biggest Losers Have Recovered Their Lossesfinnhub.io
- AMD Just Guided to More Revenue Than Intel. A Decade Ago Intel Was 12x Its Sizefinnhub.io
- Google, Nvidia, AMD And Others To Invest $26B In Anthropic Alongside IPOfinnhub.io
- Advanced Micro Devices soars 13% on Google Cloud deal, tech rallyseekingalpha.com
- AMD Lands Key Role in Google's New AI Chip System as Nvidia Rivalry Intensifiesbenzinga.com
- AMD Joins Google AI Chip Push Against Nvidia - Advanced Micro Devices (NASDAQ:AMD) - Benzinganews.google.com
Our call
Buy moredated Nov 11, 2026
Advanced Micro Devices' sales grew 42% over the past year, and its report on Nov 3 beat profit forecasts by 9.5%. We'd stop buying if Advanced Micro Devices' next report shows sales growth below 21% or misses profit forecasts.
Other moves on Nov 10
- HIMS−16.5%Earnings miss and weaker outlook trigger Hims & Hers selloff
- LFVN−13.6%LifeVantage Stock Falls After Revenue Drops 22%
- QLYS−13.3%Qualys Falls Despite Earnings Beat on Tepid Revenue Outlook
- ACAD+10.7%Revenue Beat and Guidance Lift Acadia Shares
- ASTS−8.7%AST SpaceMobile slides after earnings miss and price-target cut
- BDSX−8.5%Analyst trims Biodesix target despite maintaining Buy rating